These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16227779)

  • 61. Old wine into new bottles. A critical evaluation of transdermal clonidine in the treatment of hypertension.
    Mathias CJ
    Clin Auton Res; 1993 Dec; 3(6):355. PubMed ID: 8193520
    [No Abstract]   [Full Text] [Related]  

  • 62. Antihypertensive effects of a new transdermal delivery system for clonidine (M-5041T) in spontaneously hypertensive rats.
    Ishii R; Naruse T; Tagawa T; Yamahata T; Dote S; Hamada K; Ishida T; Funabiki K; Namba K
    Arch Int Pharmacodyn Ther; 1994; 327(3):294-308. PubMed ID: 7848013
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children.
    Ke GM; Wang L; Xue HY; Lu WL; Zhang X; Zhang Q; Guo HY
    Biol Pharm Bull; 2005 Feb; 28(2):305-10. PubMed ID: 15684489
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rebound hypertension after discontinuation of transdermal clonidine.
    Schmidt GR; Schuna AA
    Clin Pharm; 1988 Oct; 7(10):772-4. PubMed ID: 3233898
    [No Abstract]   [Full Text] [Related]  

  • 65. Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial.
    Baumgartner GR; Rowen RC
    South Med J; 1991 Mar; 84(3):312-21. PubMed ID: 2000517
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Transcription medication error with transdermal clonidine.
    Mallet L; Cooper JW
    South Med J; 1988 Dec; 81(12):1597-8. PubMed ID: 3201308
    [No Abstract]   [Full Text] [Related]  

  • 67. [Clonidine transdermal therapeutic system in essential hypertension: effect and tolerance].
    Groth H; Vetter H; Knüsel J; Boerlin HJ; Walger P; Baumgart P; Wehling M; Siegenthaler W; Vetter W
    Schweiz Med Wochenschr; 1983 Dec; 113(49):1841-5. PubMed ID: 6676936
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Randomized, controlled trial of transdermal clonidine for smoking cessation.
    Hilleman DE; Mohiuddin SM; Delcore MG; Lucas BD
    Ann Pharmacother; 1993 Sep; 27(9):1025-8. PubMed ID: 8219431
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The efficacy of a transdermal formulation of clonidine in mild to moderate hypertension and its effects on the arterial and venous vasculature of the forearm.
    Achimastos A; Girerd X; Simon AC; Pithois-Merli I; Levenson J
    Eur J Clin Pharmacol; 1987; 33(2):111-4. PubMed ID: 3691604
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The sympathetic nervous system and hypertension: mechanisms and treatment.
    Weber MA
    Clin Auton Res; 1993 Dec; 3(6):397-8. PubMed ID: 8193528
    [No Abstract]   [Full Text] [Related]  

  • 71. The use of transdermal clonidine in the hypertensive patient with chronic renal failure.
    Lowenthal DT; Saris SD; Paran E; Cristal N
    Clin Nephrol; 1993 Jan; 39(1):37-43. PubMed ID: 8428406
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New indices in the evaluation of clonidine transdermal therapy of hypertension.
    de Leonardis V; de Scalzi M; Becucci A; Lusini C; Cinelli P
    Int J Clin Pharmacol Res; 1989; 9(5):341-5. PubMed ID: 2625373
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Transdermal clonidine therapy in elderly mild hypertensives: effects on blood pressure, plasma norepinephrine and fasting plasma glucose.
    Klein C; Morton N; Kelley S; Metz S
    J Hypertens Suppl; 1985 Dec; 3(4):S81-4. PubMed ID: 3868715
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Transdermal clonidine for the treatment of essential hypertension.
    McChesney JA; Ryan C; Shaw RE; Fishman-Rosen J; Murphy MC
    Compr Ther; 1987 Apr; 13(4):49-53. PubMed ID: 3568603
    [No Abstract]   [Full Text] [Related]  

  • 75. Hemodynamic and metabolic effects of transdermal clonidine in patients with hypertension and non-insulin-dependent diabetes mellitus.
    Giugliano D; Acampora R; Marfella R; La Marca C; Marfella M; Nappo F; D'Onofrio F
    Am J Hypertens; 1998 Feb; 11(2):184-9. PubMed ID: 9524046
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects.
    Fujimura A; Ebihara A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1994 Mar; 34(3):260-5. PubMed ID: 8021335
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Plasma dilution during transdermal clonidine antihypertensive monotherapy.
    Zawada ET; Jensen RA; Williams L; Zeigler DW; Kauker ML
    Int J Artif Organs; 1989 Mar; 12(3):200-3. PubMed ID: 2744881
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Transdermal antihypertensive for elderly hypertensives.
    Bhatia RS
    J Assoc Physicians India; 1993 May; 41(5):316. PubMed ID: 8300479
    [No Abstract]   [Full Text] [Related]  

  • 79. The use of transcutaneous clonidine hydrochloride in the patient with diabetes mellitus and mild hypertension.
    Wallin JD; Krane NK; Bergman S; Morgan M
    J Clin Hypertens; 1985 Dec; 1(4):315-21. PubMed ID: 3836300
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rebound hypertension after discontinuation of transdermal clonidine therapy.
    Metz S; Klein C; Morton N
    Am J Med; 1987 Jan; 82(1):17-9. PubMed ID: 3026180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.